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Background: Concurrent chemoradiotherapy is the standard
treatment for non-surgical care of patients with locally advanced
oesophageal cancer. Nimotuzumab (h-R3) is a genetically engi-
neered humanised monoclonal antibody that can recognise an
epitope in the extracellular domain of human epidermal
growth-factor receptor (EGFR). This phase 1 trial was designed
to assess the safety and efficacy of nimotuzumab when given
with concurrent chemoradiotherapy.
Methods: Patients age 18–75 years, with ECOG performance sta-
tus 0–2 and locally advanced squamous oesophageal cancer con-
firmed by histological assay, were eligible for the study. Patients
received radiotherapy to a total dose of 61.2 Gy/32Fx concurrent
with two cycles of PF regimen (cisplatin 25 mg/m2 days 1–3; fluoro-
uracil 600 mg/m2 continuous IV infusion days 1–3, every 28 days).
An escalating weekly fixed dose of nimotuzumab (100, 200, and
400 mg) was administered during radiotherapy in a cohort study.
After radiotherapy, patients received consolidation chemotherapy
with PF regimen every 28 days for another two cycles. The primary
endpointswere safety and early efficacy. The trial was approved by
the Chinese State Food and Drug Administration and the protocol
has passed ethical committee review and gained institutional
review board permission. The trial is registered with clinicaltri-
als.gov, number NCT00950417. All participants gave written
informed consent.
Findings: From July, 2009, to June, 2010, nine patients (seven
men and two women) with a median age of 58 years (48–72 years)
were enrolled. All patients tolerated the treatment. No adverse
events likely to be related to nimotuzumab were noted. The
objective remission rate, which can reflect early efficacy, was
66.67–75% based on the evaluable cases.
Interpretation: Nimotuzumab combined with chemoradiother-
apy based on the PF regimen was safe and well-tolerated.
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Background: Nimotuzumab is a humanised monoclonal anti-
body of epidermal growth-factor receptor (EGFR). We assessed
the safety, tolerability, and efficacy of nimotuzumab combined
with irinotecan as second-line treatment in Chinese patients with
metastatic colorectal cancer (mCRC).
Methods: Patients with mCRC refractory to oxaliplatin, wild-
type K-ras, target lesion(s), ECOG performance status 62, and
adequate organ function were eligible for this open-label, sin-
gle-arm trial (NCT00972465). Irinotecan was given as 180 mg/m2
on day 1 every 2 weeks until progression, or adverse events, for
a maximum of six cycles. Nimotuzumab was given as 200, 400,
or 600 mg weekly until progression or adverse events. Primary
endpoints were objective response rate and toxicity. Secondary
endpoints were progression-free and overall survival. Patients
gave written informed consent.
Findings A total of 22 patients (male-to-female ratio 14:8; med-
ian age 55 years, range 30–78) were enrolled from July, 2009, to
July, 2010. Four, seven, and 11 patients received nimotuzumab
at a dose of 200, 400, and 600 mg, respectively. The total number
of doses of nimotuzumab was 244 (median 6, range 2–30). No
grade 3–4 toxic effects relating to nimotuzumab were observed.
Two patients developed skin rash (grade 1): one each at the 400
and 600 mg doses. The maximum tolerated dose has not yet been
reached. Three patients (two at the 400 mg dose and one at
600 mg) dropped out for personal reasons. In the 600 mg group,
partial response was 40% (4/10) and progressive disease (PD)
was 60% (6/10). In the 400 mg group, stable disease (SD) was
20% (1/5) and PD was 80% (4/5). In the 200 mg group, SD was
50% (2/4) and PD was 50% (2/4). Follow-up of overall survival is
ongoing.
Interpretation: Addition of nimotuzumab 600 mg weekly to
irinotecan for second-line treatment of mCRC is safe, and first
data suggest promising activity. The maximum tolerated dose of
nimotuzumab has not been reached yet.
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Background: Nimotuzumab, a humanised anti-epidermal
growth-factor receptor (EGFR) monoclonal antibody, has demon-
strated efficacy and an absence of severe skin toxicity in many
phase 1 and 2 cancer trials.
Methods: We did a single-centre, randomised, parallel assign-
ment, open-label study of nimotuzumab (N: 200 mg IV on days
1, 8, and 15, every 3 weeks) plus cisplatin (C: 30 mg/m2 on days
1 and 2, every 3 weeks) plus S-1 (S: 80 mg/m2 twice daily on days
1–14, followed by 7 days off) versus cisplatin plus S-1, as first-line
treatment in patients with advanced or metastatic gastric cancer.
If tumour control was achieved, NCS and CS were continued until
unacceptable toxicity or disease progression. The primary end-
point was objective response rate (ORR) and the secondary end-
points included time-to-progression (TTP), progression-free
survival (PFS), 1-year survival rates, and safety.
Findings: 40 patients, 27 men and 13 women, with a median
age of 54 years (range 21–74) and good performance status (ECOG
PS 0–2) were treated with NCS (n = 20) or CS (n = 20). Up to January
14, 2011, 36 patients (NCS group 19 cases, CS group 17 cases) have
undergone efficacy assessment. ORR was 63.2% (12/19) in the NCS
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